Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to $7.0 million.

  • Prime Medicine's Current Deferred Revenue fell 2509.7% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 2509.7%. This contributed to the annual value of $7.1 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prime Medicine's Current Deferred Revenue stood at $7.0 million, which was down 2509.7% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Current Deferred Revenue ranged from a high of $9.3 million in Q3 2024 and a low of $7.0 million during Q3 2025